{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:07:54Z","timestamp":1790734074535,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005343.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000}}],"reference-count":201,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005343.pub4","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T11:44:47Z","timestamp":1572522287000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer"],"prefix":"10.1002","author":[{"given":"Sarah L","family":"Coleridge","sequence":"first","affiliation":[{"name":"Taunton and Somerset NHS Foundation Trust; Obstetrics and Gynaecology; Musgrove Park Hospital Taunton UK TA1 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bryant","sequence":"additional","affiliation":[{"name":"Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Lyons","sequence":"additional","affiliation":[{"name":"University of Bristol; School of Medical Sciences; 38 Kings Parade Avenue Bristol UK BS8 2RB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Goodall","sequence":"additional","affiliation":[{"name":"Imperial College London; Department of Surgery and Cancer; Kensington London UK SW7 2AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kehoe","sequence":"additional","affiliation":[{"name":"University of Birmingham; Institute of Cancer and Genomics; Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"issue":"var.pagings","key":"10.1002\/14651858.CD005343.pub4-BIB0001|cit1","first-page":"1316","article-title":"An open prospective randomized trial comparing primary complete cytoreduction surgery to debulking surgery after chemotherapy in advanced stage (FIGO's IIIC) ovarian carcinoma","volume":"Conference: 19t","author":"Chekman","year":"2015","journal-title":"Conference Publication"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Fagotti A Ferrandina G Vizzielli G Fanfani F Gallotta V Chiantera V Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome European Journal of Cancer 2016 22 33","DOI":"10.1016\/j.ejca.2016.01.017"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Fagotti A Vizzielli G Ferrandina G Fanfani F Gallotta V Chiantera V Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial) Journal of Clinical Oncology 2018 5516","DOI":"10.1200\/JCO.2018.36.15_suppl.5516"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0007|cit4","doi-asserted-by":"crossref","unstructured":"Kehoe S Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC chorus trial International Journal of Gynecological Cancer 2013 17","DOI":"10.1200\/jco.2013.31.15_suppl.5500"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Kehoe S Hook J Nankivell M Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial Journal of Clinical Oncology 2013 Abstract 5500","DOI":"10.1200\/jco.2013.31.15_suppl.5500"},{"issue":"9990","key":"10.1002\/14651858.CD005343.pub4-BIB0004|cit6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0006|cit7","unstructured":"Kehoe S Wheeler S CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma www.ctu.mrc.ac.uk\/plugins\/StudyDisplay\/protocols\/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http:\/\/www.ctu.mrc.ac.uk\/research_areas\/study_details.aspx?s=9"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0008|cit8","unstructured":"Law K Murray C Kehoe S CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma Proceedings of the Annual Meeting of the British Gynaecological Cancer Society; 2006: Nov 30-Dec 1; Manchester, UK 90"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jjco\/hym145","article-title":"Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602","volume":"38","author":"Onda","year":"2008","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","article-title":"Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602","volume":"64","author":"Onda","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Onda T Satoh T Saito T Kasamatsu T Nakanishi T Takehara K Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602 Journal of Clinical Oncology 2018","DOI":"10.1200\/JCO.2018.36.15_suppl.5500"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0013|cit13","first-page":"S620","article-title":"Quality of life in advanced ovarian cancer patients: A randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy","volume":"21","author":"Greimel","year":"2011","journal-title":"International Journal of Gynaecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2013.08.014","article-title":"Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy","volume":"131","author":"Greimel","year":"2013","journal-title":"Gynaecoloic Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005343.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","article-title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","volume":"47","author":"Vergote","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0017|cit17","unstructured":"Vergote I Pecorelli S Stuart G Intergroup Study (EORTC 55971\/NCIC OV13). Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma Trial protocol: http:\/\/www.cancer.gov\/clinicaltrials\/EORTC-55971"},{"issue":"10","key":"10.1002\/14651858.CD005343.pub4-BIB0019|cit18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"31","key":"10.1002\/14651858.CD005343.pub4-BIB0018|cit19","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2011.36.9785","article-title":"Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer","volume":"29","author":"Vergote","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2010.08.008","article-title":"Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971\/NCIC-CTG OV13 neoadjuvant trial","volume":"47","author":"Verleye","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"12","key":"10.1002\/14651858.CD005343.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U","article-title":"Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study","volume":"91","author":"Ansquer","year":"2001","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ijgc-00009577-200311001-00006","article-title":"The potential role of neoadjuvant chemotherapy in advanced ovarian cancer","volume":"13 Suppl 2","author":"Baekelandt","year":"2003","journal-title":"International Journal of Gynecological Cancer"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0090-8258(90)90042-J","article-title":"Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study","volume":"38","author":"Bertelsen","year":"1990","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0024|cit24","first-page":"423","article-title":"Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - preliminary results","volume":"26","author":"Bidzinski","year":"2005","journal-title":"European Journal of Gynaecological Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0025|cit25","unstructured":"Bristow R Tomacruz RS Armstrong DK Trimble EL Montz FJ Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6,848 patients Proceedings of the American Society of Clinical Oncology 2001 (Abstract 807) 202a"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0090-8258(90)90361-N","article-title":"Neoadjuvant chemotherapy in stage X ovarian carcinoma","volume":"37","author":"Chambers","year":"1990","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/gyno.2002.6849","article-title":"Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study","volume":"88","author":"Chan","year":"2003","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Chan JK Brady MF Penson RT Monk BJ Kapp DS Birrer MJ Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262 Gynecologic Oncology 2017 68","DOI":"10.1016\/j.ygyno.2017.03.161"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2011.08.014","article-title":"An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)","volume":"124","author":"Chi","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/IGC.0000000000001271","article-title":"Economic analysis of neoadjuvant chemotherapy versus primary debulking surgery for advanced epithelial ovarian cancer using an aggressive surgical paradigm","volume":"28","author":"Cole","year":"2018","journal-title":"International Journal of Gynecologic Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0031|cit31","first-page":"135","article-title":"Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients","volume":"35","author":"Colombo","year":"2009","journal-title":"Journal of Cancer Surgery"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0032|cit32","first-page":"453-8 POINT and","article-title":"Point\/Counterpoint: Primary debulking surgery versus neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer","volume":"31(6)","author":"Cowan","year":"2017","journal-title":"Oncology (Williston Park)"},{"issue":"15, Supplement","key":"10.1002\/14651858.CD005343.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1200\/jco.2014.32.15_suppl.5588","article-title":"Primary versus interval debulking surgery and the risk to induce platinum resitance","volume":"32","author":"Costa","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1477-7819-11-267","article-title":"A meta-analysis: Neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stage III and IV","volume":"11","author":"Dai-yuan","year":"2013","journal-title":"World Journal of Surgical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Daniele G Lorusso D Scambia G Cecere SC Nicoletto MO Breda E Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial Gynecologic Oncology 2017 256 9","DOI":"10.1016\/j.ygyno.2016.12.011"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0036|cit36","unstructured":"Deval BP Platini C Combe M Boiron C Mignot L Geay J Surgery: an option for patients with FIGO stage IV ovarian cancer treated by platinum-paclitaxel-based regimen? A GINECO study Proceedings of the American Society of Clinical Oncology 2003 452; Abstract 1817"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-004-0993-9","article-title":"Neoadjuvant chemotherapy for epithelial ovarian cancer - role of apoptosis","volume":"56","author":"Dutta","year":"2005","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0038|cit38","unstructured":"Abstracts from 18th International Meeting of the European Society of Gynaecological Oncology, ESGO 2013 International Journal of Gynecological Cancer 2013"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0039|cit39","first-page":"28","article-title":"Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer","volume":"28","author":"Evdokimova","year":"1982","journal-title":"Voprosy Onkologii"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajog.2006.03.075","article-title":"Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III\/IV epithelial ovarian cancer","volume":"195","author":"Everett","year":"2006","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/IGC.0000000000000200","article-title":"Differences in regional diagnostic strategies and in intended versus actual first-line treatment of patients with advanced ovarian cancer in denmark","volume":"24","author":"Fag\u00f6-Olsen","year":"2014","journal-title":"International Journal of Gynecological Cancer"},{"issue":"12","key":"10.1002\/14651858.CD005343.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(18)30625-9","article-title":"Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer","volume":"19","author":"Fagotti","year":"2018","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000074644","article-title":"Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients","volume":"65","author":"Fanfani","year":"2003","journal-title":"Oncology"},{"issue":"8","key":"10.1002\/14651858.CD005343.pub4-BIB0044|cit44","first-page":"722","article-title":"Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer","volume":"111","author":"Feng","year":"1998","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2015.01.271","article-title":"Primary debulking surgery and neo-adjuvant chemotherapy in the Medicare population: An analysis of cost of care","volume":"137","author":"Forde","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11912-013-0313-9","article-title":"Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed?","volume":"15","author":"Fujiwara","year":"2013","journal-title":"Current Oncology Reports"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0047|cit47","first-page":"719","article-title":"Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery","volume":"9","author":"Ghaemmaghami","year":"2008","journal-title":"Asia Pacific Journal of Cancer Prevention"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0048|cit48","first-page":"25","article-title":"Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma","volume":"27","author":"Giannopoulos","year":"2006","journal-title":"European Journal of Gynaecological Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0049|cit49","unstructured":"Grosso LG Lotti M Rossetti D Ansaloni L Frigerio L Cytoreduction and hipec vs only cytoreduction surgery after neoajuvant chemotherapy for treatment of ovarian cancer naive patients : A phase III multi center randomized ongoing trial International Journal of Gynecological Cancer 2013 897"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0050|cit50","unstructured":"Hanker LC Complete surgical debulking in advanced ovarian carcinoma improves prognosis in any FIGO stage: analysis of 3,126 prospectively randomized patients in AGO-OVAR\/GINECO phase 3 trials Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynecology and Obstetrics (Deutsche Gesellschaft fur Gynakologie und Geburtshilfe, DGGG October 2010"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1477-7819-3-57","article-title":"Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma","volume":"3","author":"Hegazy","year":"2005","journal-title":"World Journal of Surgical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2006.11.025","article-title":"Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease","volume":"105","author":"Hou","year":"2007","journal-title":"Gynecological Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-6-153","article-title":"Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients","volume":"6","author":"Inciura","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0054|cit54","unstructured":"Abstracts of the 3rd International and 18th National Congress of Iranian Society for Reproductive Medicine Iranian Journal of Reproductive Medicine 2012"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0090-8258(91)90335-3","article-title":"Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer","volume":"42","author":"Jacob","year":"1991","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0056|cit56","unstructured":"Kayikcioglu F Kose MF Boran N Ozdas E Ozgul N Tulunay G Neoadjuvant chemotherapy in advanced stage ovarian carcinoma VIII Meeting of the International Gynecologic Cancer Society Buenos Aires, Argentina 2000 Abstract 48"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1525-1438.2001.01064.x","article-title":"Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma","volume":"11","author":"Kayikcioglu","year":"2001","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0058|cit58","first-page":"S678","article-title":"Problems recruiting to surgical trials: Examples from the MRC\/NRCI chorus randomised clinical trial","volume":"21","author":"Kehoe","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"issue":"10","key":"10.1002\/14651858.CD005343.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1002\/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#","article-title":"Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC Ovarian Carcinoma","volume":"92","author":"Kuhn","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bpobgyn.2015.02.008","article-title":"Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging","volume":"29","author":"Kumar","year":"2015","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0061|cit61","first-page":"61","article-title":"Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer","volume":"73","author":"Lawton","year":"1989","journal-title":"Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1447-0756.2006.00359.x","article-title":"Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery","volume":"32","author":"Lee","year":"2006","journal-title":"Journal of Obstetric and Gynaecological Research"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3802\/jgo.2018.29.e63","article-title":"Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center","volume":"29","author":"Lee","year":"2018","journal-title":"Journal of Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0936-6555(05)80227-4","article-title":"Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma","volume":"5","author":"Lim","year":"1993","journal-title":"Clinical Oncology (Royal College of Radiologists (Great Britain))"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0065|cit65","first-page":"343","article-title":"Advanced ovarian cancer: combination chemotherapy and cytoreductive surgery","volume":"16","author":"Liu","year":"1995","journal-title":"Acta Academiae Medicinae Hubei"},{"issue":"10","key":"10.1002\/14651858.CD005343.pub4-BIB0066|cit66","first-page":"1547","article-title":"Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma","volume":"117","author":"Liu","year":"2004","journal-title":"Chinese Medical Journal (Engl)"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Liu J Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer Gynecologic Oncology 2015 176","DOI":"10.1016\/j.ygyno.2015.01.441"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0068|cit68","unstructured":"Liu EL Mi RR Wang DH Wang LQ Zhang YM Chen WM Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites Euroepean Journal of Gynaecological Oncology 2017 209 13"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1525-1438.2005.15206.x","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study","volume":"15","author":"Loizzi","year":"2005","journal-title":"International Journal of Gynecological Cancer"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0070|cit70","first-page":"578","article-title":"Intra-arterial chemotherapy in advanced ovarian cancers 2. Therapeutic results in relation to prognostic factors","volume":"109","author":"Lotze","year":"1987","journal-title":"Zentralblatt f\u00fcr Gyn\u00e4kologie"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0071|cit71","first-page":"278","article-title":"Primary treatment of ovarian cancer","volume":"125","author":"Lyngstadaas","year":"2005","journal-title":"Tidsskrift for den Norske Laegeforening"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3747\/co.v18i2.725","article-title":"Phase II\/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21","volume":"18","author":"Mackay","year":"2011","journal-title":"Current Oncology"},{"issue":"S3","key":"10.1002\/14651858.CD005343.pub4-BIB0073|cit73","first-page":"659","article-title":"Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer. A randomized multicenter phase II study (PRIMOVAR)","volume":"16","author":"Mahner","year":"2006","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0074|cit74","unstructured":"Mahner S Harter P Hilpert F Pfisterer J Du Bois A Chi D Neoadjuvant or postoperative therapy for advanced ovarian cancer Oncology research and treatment 2014 116"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Makar AP Trope CG Tummers P Denys H Vandecasteele K Advanced ovarian cancer: primary or interval debulking? five categories of patients in view of the results of randomized trials and tumor biology: primary debulking surgery and interval debulking surgery for advanced ovarian cancer Oncologist 2016 745 54","DOI":"10.1634\/theoncologist.2015-0239"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0076|cit76","first-page":"309","article-title":"Neo-adjuvant chemotherapy in ovarian carcinoma (case report)","volume":"73","author":"Malzoni","year":"1993","journal-title":"Rassegna Internazionale di Clinica e Terapia"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0090-8258(03)00249-X","article-title":"Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer","volume":"90","author":"Mazzeo","year":"2003","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1136\/bmj.j5463","article-title":"Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study","volume":"360","author":"Melamed","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jamcollsurg.2003.06.004","article-title":"Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer","volume":"197","author":"Morice","year":"2003","journal-title":"Journal of the American College of Surgeons"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/030089168807400513","article-title":"Timing of surgery and the role of cytoreductive chemotherapy in patients with advanced ovarian carcinoma","volume":"74","author":"Negretti","year":"1988","journal-title":"Tumori"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.01.022","article-title":"Personalized surgical therapy for advanced ovarian cancer","volume":"137","author":"Nick","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0082|cit82","first-page":"591","article-title":"Treatment outcomes for advanced ovarian cancers with peritoneal dissemination","volume":"38","author":"Oe","year":"2011","journal-title":"Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy]"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2008.12.027","article-title":"Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III\/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206","volume":"113","author":"Onda","year":"2009","journal-title":"Gynecologic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0084|cit84","first-page":"393","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer","volume":"17","author":"Onnis","year":"1996","journal-title":"European Journal of Gynaecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3892\/or_00000479","article-title":"Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR)","volume":"22","author":"Polcher","year":"2009","journal-title":"Oncology Reports"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jval.2015.01.005","article-title":"Cost-effectiveness of neoadjuvant chemotherapy versus primary surgery in elderly patients with advanced ovarian cancer","volume":"18","author":"Poonawalla","year":"2015","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2016.04.512","article-title":"Effect of perioperative blood transfusion on quality of life, progression-free and overall survival in primary treatment of advanced epithelial ovarian cancer: an EORTC ancillary study","volume":"141","author":"Prescott","year":"2016","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.18632\/oncotarget.23808","article-title":"The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies","volume":"9","author":"Qin","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/01.IGC.0000434300.99639.61","article-title":"Randomized study of aggressive surgery for advanced ovarian cancer","volume":"23","author":"Querleu","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1525-1438.2007.00905.x","article-title":"Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study","volume":"17","author":"Rafii","year":"2007","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaoncol.2016.4411","article-title":"Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database","volume":"3","author":"Rauh-Hain","year":"2017","journal-title":"JAMA oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0092|cit92","first-page":"287","article-title":"Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study","volume":"22","author":"Recchia","year":"2001","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1471-0528.1994.tb13080.x","article-title":"Intervention debulking surgery in advanced epithelial ovarian cancer","volume":"101","author":"Redman","year":"1994","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Robova H Rob L Pluta M Kacirek J Strnad P Schlegerova D Neoadjuvant chemotherapy in patients with primary unresectable ovarian cancer International Journal of Gynecological Cancer 2003 44","DOI":"10.1136\/ijgc-00009577-200303001-00154"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Rowland M Farris C Lesnock J Krivak T Neoadjuvant chemotherapy is less costly than primary debulking surgery for treatment of advanced stage ovarian cancer in patients > 65 years old Gynecologic Oncology 2013 278 9","DOI":"10.1016\/j.ygyno.2013.04.030"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"763.e1","DOI":"10.1016\/j.ajog.2015.01.053","article-title":"Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older","volume":"212","author":"Rowland","year":"2015","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-12-31","article-title":"Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study","volume":"12","author":"Rutten","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000271373","article-title":"Surgery in the treatment concept of epithelial ovarian cancer","volume":"30 Suppl 1","author":"Salzer","year":"1990","journal-title":"Gyn\u00e4kologische Rundschau"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834014544891","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: Latest results and place in therapy","volume":"6","author":"Sato","year":"2014","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13224-013-0425-z","article-title":"Comparison of platinum-based neoadjuvant chemotherapy and primary debulking surgery in patients with advanced ovarian cancer","volume":"63","author":"Sayyah-Melli","year":"2013","journal-title":"Journal of Obstetrics and Gynaecology of India"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ygyno.2014.10.007","article-title":"Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter?","volume":"135","author":"Schorge","year":"2014","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/gyno.1994.1083","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer","volume":"53","author":"Schwartz","year":"1994","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/gyno.1998.5236","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival","volume":"72","author":"Schwartz","year":"1999","journal-title":"Gynecologic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ijgc-00009577-200309000-00003","article-title":"Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors","volume":"13","author":"Shibata","year":"2003","journal-title":"International Journal of Gynecological Cancer"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0105|cit105","first-page":"1007","article-title":"Treatment of stage III and IV ovarian cancer - is neoadjuvant chemotherapy effective?","volume":"45","author":"Shimizu","year":"1993","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005343.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ijgc-00009577-200602001-00008","article-title":"A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer","volume":"16","author":"Steed","year":"2006","journal-title":"International Journal of Gynecological Cancer"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0107|cit107","first-page":"625","article-title":"Therapeutic strategy in the management of stage II - IV epithelial ovarian carcinoma","volume":"113","author":"Sun","year":"2000","journal-title":"Chinese Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0108|cit108","first-page":"468","article-title":"Cytoreductive surgery in advanced ovarian cancer with or without neoadjuvant chemotherapy","volume":"72","author":"Surwit","year":"1999","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00404-013-2924-7","article-title":"Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer","volume":"288","author":"Taskin","year":"2013","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2015.01.292","article-title":"Neoadjuvant chemotherapy reduces operative morbidity without effecting time to recurrence in advanced stage epithelial ovarian cancer","volume":"137","author":"Taylor","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2017.12.015","article-title":"Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase","volume":"148","author":"Tran","year":"2018","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0112|cit112","first-page":"357","article-title":"Primary debulking surgery is not an independent prognostic factor in advanced stage IIIC ovarian carcinoma","volume":"64","author":"Trope","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0113|cit113","first-page":"185","article-title":"Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer","volume":"87","author":"Ushijima","year":"2002","journal-title":"International Surgery"},{"issue":"10","key":"10.1002\/14651858.CD005343.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"Burg","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD005343.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2013.06.013","article-title":"Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial","volume":"49","author":"Meurs","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD005343.pub4-BIB0116|cit116","first-page":"4","article-title":"A randomised trial of intervention debulking surgery and the duration of cis-platinum combination chemotherapy in advanced epithelial ovarian cancer (EOC)","volume":"1","author":"Varma","year":"1990.","journal-title":"Annals of Oncology, ESMO Congress"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1006\/gyno.1998.5213","article-title":"Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients","volume":"71","author":"Vergote","year":"1998","journal-title":"Gynecologic Oncology"},{"issue":"3 Suppl 7","key":"10.1002\/14651858.CD005343.pub4-BIB0118|cit118","first-page":"31","article-title":"Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer","volume":"27","author":"Vergote","year":"2000","journal-title":"Seminars in Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0119|cit119","first-page":"405","article-title":"Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study","volume":"23","author":"Vrscaj","year":"2002","journal-title":"European Journal of Gynaecological Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Wenzel L Mukamel D Osann K Havrilesky L Sparks L Lipscomb J Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: a personalized decision tool for newly diagnosed ovarian cancer patients Contemporary Clinical Trials 2017 29 36","DOI":"10.1016\/j.cct.2017.03.006"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Wright J Ananth C Herzog T Burke W Lu Y Lewin S Comparative effectiveness of upfront treatment strategies for advanced-stage ovarian cancer Gynecologic Oncology 2013 e117","DOI":"10.1016\/j.ygyno.2013.04.337"},{"issue":"8","key":"10.1002\/14651858.CD005343.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.28508","article-title":"Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer","volume":"120","author":"Wright","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0123|cit123","first-page":"650","article-title":"Efficacy of neoadjuvant chemotherapy in advanced ovarian cancer. [Chinese]","volume":"27","author":"Wu","year":"2012","journal-title":"Journal of Practical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Xiao Y Xie S Zhang N Wang J Lv C Guo J Platinum-based neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: a systematic review and meta-analysis Gynecologic and Obstetric Investigation 2017 209 18","DOI":"10.1159\/000485618"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0125|cit125","first-page":"10","article-title":"Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome","volume":"12","author":"Yang","year":"2017","journal-title":"PLOS One e0186725"},{"issue":"15","key":"10.1002\/14651858.CD005343.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1200\/jco.2014.32.15_suppl.tps5624","article-title":"Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer","volume":"32","author":"Zamagni","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"35914","DOI":"10.1038\/srep35914","article-title":"Neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: a meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0128|cit128","unstructured":"Janga D Kumar L Kumar S Shukla NK Thulkar S Singh R Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study Proceedings of the American Society of Clinical Oncology 2003 487"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Kumar L Hariprasad R Kumar S Bhatla N Shukla N Thulkar S Neoadjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a phase III randomized study Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I (June 20 Supplement) 2006 18 Suppl","DOI":"10.1200\/jco.2006.24.18_suppl.15000"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0130|cit130","first-page":"15","article-title":"Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a prospective, randomized study","volume":"30","author":"Kumar","year":"2009","journal-title":"Indian Journal of Medical and Paediatric Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0132|cit131","doi-asserted-by":"crossref","unstructured":"Kumar L Hariprasad R Kumar S Bhatla N Thulkar S Vijayaraghavan M Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results Journal of Clinical Oncology; ASCO Annual Meeting Proceedings Part I Chicago, Illinois 2007 5531","DOI":"10.1200\/jco.2007.25.18_suppl.5531"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0131|cit132","doi-asserted-by":"crossref","unstructured":"Kumar L Hariprasad R Kumar S Bhatla N Thulkar S Vijayaraghavan M Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement) 2007 5531","DOI":"10.1200\/jco.2007.25.18_suppl.5531"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0133|cit133","first-page":"89","article-title":"Neoadjuvant chemotherapy in stage III & IV epithelial ovarian carcinoma (EOC)","volume":"16","author":"Kumar","year":"2003","journal-title":"Journal International Medical Sciences Academy"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Mahner S Heitz F Burges A Reuss A Kraemer B Schmalfeldt B TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 \/ AGO-OVAR OP7) Journal of clinical oncology. Conference: 2017 annual meeting of the American Society of Clinical Oncology, ASCO. United states 912 0139;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States. American Society of Clinical Oncology 0139 912 2017 (no pagination)","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5602"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Mahner S Heitz F Burges A Reuss A Kramer B Schmalfeldt B Role of neoadjuvant chemotherapy in advanced ovarian cancer: TRUST-trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 \/ AGO-OVAR OP7) Annual Meeting of German, Austrian and Swiss Societies for Hematology and Medical Oncology 2017. Societies of Hematology and Medical Oncology 2017 Berlin Karger AG 0142 825 2017","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS5602"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0136|cit136","unstructured":"NCT02859038 Study of upfront surgery versus neoadjuvant chemotherapy in patients with advanced ovarian cancer (SUNNY) ClinicalTrials.gov 2016"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0137|cit137","first-page":"349","article-title":"A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary","volume":"16","author":"Allen","year":"1995","journal-title":"European Journal of Gynaecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007697.pub2","article-title":"Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer","author":"Ang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1097\/IGC.0000000000001108","article-title":"The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer: results from a multi-institutional study","volume":"27","author":"Bogani","year":"2017","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2006.11.002","article-title":"Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction","volume":"104","author":"Bristow","year":"2007","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0090-8258(91)90099-Q","article-title":"Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer","volume":"40","author":"Burghardt","year":"1991","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0144|cit144","unstructured":"Chi D An analysis of patients with bulky stage IIIC\/IV ovarian, tubal and peritoneal carcinoma treated with primary debulking surgery (PDS) during the same period as the randomized EORTC-NCIC trial of PDS versus neoadjuvant chemotherapy Gynecologic Oncology Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists; 2010 Mar 14-17, 2010 San Francisco, CA 2010"},{"issue":"31","key":"10.1002\/14651858.CD005343.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2011.35.9935","article-title":"Is the easier way ever the better way?","volume":"29","author":"Chi","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl","key":"10.1002\/14651858.CD005343.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"abstr 5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","article-title":"A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology\/Gynecologic Oncology Group (GOG) study","volume":"36","author":"Coleman","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0147|cit147","unstructured":"Cancer Research UK Cancer Research UK ovarian cancer fact sheet http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0148|cit148","unstructured":"CTCAE Common Terminology Criteria for Adverse Events (https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf))"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0149|cit149","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Egger M, Davey Smith G, Altman DG (eds).\u00a0Systematic Reviews in Health Care: Meta-Analysis in Context (2nd edition)","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2010.06.021","article-title":"The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists","volume":"119","author":"Dewdney","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire(GINECO)","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD005343.pub4-BIB0153|cit153","first-page":"1165","article-title":"Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer","volume":"21","author":"du Bois","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"issue":"15_suppl","key":"10.1002\/14651858.CD005343.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1056\/NEJMe1900044","article-title":"Ovarian cancer surgery - heed this LION\u2019s roar","volume":"380","author":"Eisenhauer","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.ejca.2015.08.001","article-title":"The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods","volume":"51","author":"Rossi","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD005343.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Annal of Surgical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2013.07.016","article-title":"A multicentric trial (Olympia- MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer","volume":"209","author":"Fagotti","year":"2013","journal-title":"American Journal of Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","author":"FIGO Committee in Gynecologic Oncology","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0161|cit161","first-page":"394-424","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0162|cit162","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT [Computer program] 2015"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the relaibility and validity of a disease specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0164|cit164","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"National Cancer Institute Monograph"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1245\/s10434-019-07516-3","article-title":"Maximal-effort cytoreductive surgery for ovarian cancer patients with a high tumor burden: variations in practice and impact on outcome","volume":"26","author":"Hall","year":"2019","journal-title":"Annals of Surgical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","article-title":"A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms","volume":"380","author":"Harter","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0168|cit168","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD005343.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0002-9378(92)91658-W","article-title":"Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?","volume":"166","author":"Hunter","year":"1992","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"8","key":"10.1002\/14651858.CD005343.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Annals of Surgical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bjc.1994.440","article-title":"The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma","volume":"70","author":"Kehoe","year":"1994","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"2","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD005343.pub4-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004706.pub5","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Lawrie","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1\u22126","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamideand cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0177|cit177","first-page":"(study subseque","article-title":"WITHDRAWN: Adjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma","volume":"Epub ahead of p","author":"Melis","year":"2016","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin andpaclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jjco\/hyp127","article-title":"The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment","volume":"40","author":"Onda","year":"2010","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD005343.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/era.11.24","article-title":"Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions","volume":"11","author":"Onda","year":"2011","journal-title":"Expert Reviews in Anticancer Therapy"},{"issue":"5","key":"10.1002\/14651858.CD005343.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC QLQ-C30 in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Quality of Life Research"},{"issue":"24","key":"10.1002\/14651858.CD005343.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0090-8258(91)90032-Z","article-title":"Pretherapeutic scalene lymph node biopsy in ovarian cancer","volume":"43","author":"Petru","year":"1991","journal-title":"Gynecologic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD005343.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0185|cit185","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0187|cit187","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P and Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. Edited by: Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0188|cit188","first-page":"7-30","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11912-009-0062-y","article-title":"Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer","volume":"11","author":"Swart","year":"2009","journal-title":"Current Oncology Reports"},{"issue":"1","key":"10.1002\/14651858.CD005343.pub4-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006014.pub7","article-title":"Interval debulking surgery for advanced epithelial ovarian cancer","author":"Tangjitgamol","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"31","key":"10.1002\/14651858.CD005343.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2011.36.9785","article-title":"Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer","volume":"29","author":"Vergote","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005343.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0959-8049(11)70152-6","article-title":"Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer","volume":"47","author":"Vergote","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"32","key":"10.1002\/14651858.CD005343.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2016.69.7458","article-title":"How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma","volume":"34","author":"Vergote","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1002\/14651858.CD005343.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1245\/s10434-014-3783-6","article-title":"Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience","volume":"21","author":"Vizzielli","year":"2014","journal-title":"Annals of Surgical Oncology"},{"key":"10.1002\/14651858.CD005343.pub4-BIB0198|cit198","first-page":"1246-54","article-title":"Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer","volume":"120 (8)","author":"Wright","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD005343.pub4-BIB0199|cit199","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005343.pub4-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub2","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD005343.pub4-BIB0201|cit201","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub3","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005343.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005343.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T03:19:43Z","timestamp":1664767183000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005343.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":201,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005343.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD005343.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]}}}